Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

XBRL 30 June 2019 filed with the SEC

September 2, 2019October 10, 2019 Alterity Therapeutics

XBRL 30 June 2019 filed with the SEC

Post navigation

Quarterly Cash Flow Report

Alterity Therapeutics to Present at the Janney Healthcare Conference in New York

Recent Posts

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy
Alterity to Present at Life Sciences Investor Forum
Alterity Therapeutics to Present at the GCFF Virtual Conference 2022 – Investing in Healthcare
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy
Alterity Therapeutics to Participate in the Benchmark Company Healthcare House Call Conference

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065